Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intec Pharma Ltd (NASDAQ: NTEC), Depomed (NASDAQ: DEPO) and Momenta Pharma (NASDAQ: MNTA)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intec Pharma Ltd (NASDAQ: NTEC), Depomed (NASDAQ: DEPO) and Momenta Pharma (NASDAQ: MNTA).

Intec Pharma Ltd (NASDAQ: NTEC)

Roth Capital analyst Michael Higgins reiterated a Buy rating on Intec Pharma Ltd (NASDAQ: NTEC) today and set a price target of $9.50. The company’s shares opened today at $4.90.

According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -18.3% and a 29.5% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Sucampo Pharmaceuticals, Juniper Pharmaceuticals, and Zynerba Pharmaceuticals.

Intec Pharma Ltd has an analyst consensus of Moderate Buy.

Depomed (NASDAQ: DEPO)

In a report released today, Scott Henry from Roth Capital reiterated a Buy rating on Depomed (NASDAQ: DEPO), with a price target of $28. The company’s shares opened today at $19.21.

According to TipRanks.com, Henry is a 1-star analyst with an average return of -2.4% and a 36.4% success rate. Henry covers the Healthcare sector, focusing on stocks such as Acerus Pharmaceuticals Corporation, Flamel Technologies S.A., and Apricus Biosciences Inc.

Currently, the analyst consensus on Depomed is Moderate Buy and the average price target is $28, representing a 45.8% upside.

In a report released today, JMP Securities also reiterated a Buy rating on the stock.
Momenta Pharma (NASDAQ: MNTA)

Cowen & Co. analyst Ritu Baral reiterated a Hold rating on Momenta Pharma (NASDAQ: MNTA) today and set a price target of $13. The company’s shares opened today at $11.05.

Baral said:

“MNTA recorded $29.1M rev in Q3, well above consensus estimates of $25.7M.”

According to TipRanks.com, Baral is a 2-star analyst with an average return of 0.0% and a 35.2% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Intra-Cellular Therapies.

Momenta Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $19.